Baillie Gifford & Co’s bluebird bio BLUE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-43
| Closed | -$2.73K | – | 315 |
|
|
2023
Q1 | $2.73K | Hold |
43
| – | – | ﹤0.01% | 434 |
|
|
2022
Q4 | $5.95K | Hold |
43
| – | – | ﹤0.01% | 439 |
|
|
2022
Q3 | $5K | Hold |
43
| – | – | ﹤0.01% | 443 |
|
|
2022
Q2 | $4K | Hold |
43
| – | – | ﹤0.01% | 460 |
|
|
2022
Q1 | $4K | Hold |
43
| – | – | ﹤0.01% | 475 |
|
|
2021
Q4 | $9K | Sell |
43
-23
| -35% | -$5.43K | ﹤0.01% | 452 |
|
|
2021
Q3 | $16K | Hold |
66
| – | – | ﹤0.01% | 392 |
|
|
2021
Q2 | $28K | Sell |
66
-4
| -6% | -$1.58K | ﹤0.01% | 324 |
|
|
2021
Q1 | $28K | Sell |
70
-1,731
| -96% | -$852K | ﹤0.01% | 303 |
|
|
2020
Q4 | $1.01M | Sell |
1,801
-52,785
| -97% | -$33.5M | ﹤0.01% | 249 |
|
|
2020
Q3 | $38.1M | Buy |
54,586
+845
| +2% | +$659K | 0.03% | 164 |
|
|
2020
Q2 | $42.5M | Buy |
53,741
+40
| +0.1% | +$30.2K | 0.03% | 140 |
|
|
2020
Q1 | $32M | Hold |
53,701
| – | – | 0.03% | 129 |
|
|
2019
Q4 | $61M | Sell |
53,701
-213,088
| -80% | -$232M | 0.06% | 119 |
|
|
2019
Q3 | $317M | Sell |
266,789
-59,268
| -18% | -$90.5M | 0.36% | 65 |
|
|
2019
Q2 | $537M | Sell |
326,057
-19,730
| -6% | -$34.1M | 0.57% | 46 |
|
|
2019
Q1 | $705M | Sell |
345,787
-3,861
| -1% | -$6.8M | 0.77% | 29 |
|
|
2018
Q4 | $449M | Sell |
349,648
-8,832
| -2% | -$13.5M | 0.58% | 46 |
|
|
2018
Q3 | $678M | Sell |
358,480
-15,430
| -4% | -$31.9M | 0.73% | 29 |
|
|
2018
Q2 | $760M | Sell |
373,910
-15,338
| -4% | -$35M | 0.82% | 28 |
|
|
2018
Q1 | $861M | Sell |
389,248
-11,299
| -3% | -$28.7M | 1.01% | 23 |
|
|
2017
Q4 | $924M | Sell |
400,547
-10,173
| -2% | -$20.7M | 1.15% | 19 |
|
|
2017
Q3 | $731M | Sell |
410,720
-6,211
| -1% | -$8.68M | 0.93% | 23 |
|
|
2017
Q2 | $567M | Buy |
416,931
+15,133
| +4% | +$18.3M | 0.76% | 30 |
|
|
2017
Q1 | $473M | Buy |
401,798
+3,101
| +0.8% | +$3.16M | 0.69% | 36 |
|
|
2016
Q4 | $319M | Buy |
398,697
+12,787
| +3% | +$10.2M | 0.52% | 49 |
|
|
2016
Q3 | $339M | Sell |
385,910
-4,272
| -1% | -$3.09M | 0.53% | 47 |
|
|
2016
Q2 | $219M | Buy |
390,182
+5,908
| +2% | +$3.35M | 0.39% | 57 |
|
|
2016
Q1 | $212M | Buy |
384,274
+7,282
| +2% | +$4.47M | 0.37% | 59 |
|
|
2015
Q4 | $314M | Buy |
376,992
+7,690
| +2% | +$7.68M | 0.55% | 48 |
|
|
2015
Q3 | $409M | Buy |
369,302
+83,862
| +29% | +$153M | 0.8% | 37 |
|
|
2015
Q2 | $623M | Buy |
285,440
+186,318
| +188% | +$380M | 1.12% | 22 |
|
|
2015
Q1 | $155M | Buy |
+99,122
| New | +$131M | 0.29% | 68 |
|
Other funds holding BLUE
TCM
PHS
GIM
PAMS
BBA
Baillie Gifford & Co's BLUE Position: Q2 2023 in Review
Baillie Gifford & Co sold out of bluebird bio (BLUE) in Q2 2023, closing a stake of 43 shares — an estimated $2.73K sold.
Baillie Gifford & Co first reported a position in BLUE in Q1 2015 and held it in 33 quarters. The position peaked at $924M in Q4 2017. 175 funds tracked by Wall St. Rank hold BLUE as of Q2 2023.
- Baillie Gifford & Co reported no remaining bluebird bio position as of Q2 2023 after selling out during the quarter.
- Baillie Gifford & Co sold 43 bluebird bio shares in Q2 2023, an estimated $2.73K.
- Baillie Gifford & Co first reported a position in bluebird bio in Q1 2015 and held it in 33 quarters.
- Baillie Gifford & Co's bluebird bio position peaked at $924M in Q4 2017.
- 175 funds tracked by Wall St. Rank held bluebird bio as of Q2 2023.
Based on Baillie Gifford & Co's 13F filing for Q2 2023, filed 28 Jul 2023.